UVA Cancer Center | Strategic Alliance Partners

April 28, 2021

Michael Devitt, MD, discusses utilizing PD-L1 status in biomarker-guided therapies for patients with bladder cancer.

April 09, 2021

Robert Dreicer, MD, discusses the optimal use of checkpoint inhibitors in urothelial carcinoma.

March 03, 2021

December 04, 2020

Firas El Chaer, MD, discusses the role of next-generation sequencing (NGS) in myeloproliferative neoplasms.

November 25, 2020

Firas El Chaer, MD, discusses the potential utility of combination strategies with ruxolitinib in patients with myeloproliferative neoplasms.

November 19, 2020

Emily C. Ayers, MD, discusses recent developments in chronic lymphocytic leukemia.

November 19, 2020

Kirsten ​L. Greene, MD, MAS, FACS, discusse​s the future of personalized therapy in prostate cancer.

November 17, 2020

Firas El Chaer, MD, discusses the limitations of JAK inhibitors in myelofibrosis.

April 21, 2020

Although the standard of care for muscle-invasive bladder cancer is well established, not enough patients are being treated with curative intent.

February 08, 2020

Linda R. Duska, MD, discusses primary debulking surgery in ovarian cancer.

January 29, 2020

Linda R. Duska, MD, professor of obstetrics and gynecology and gynecologic oncologist at the University of Virginia, explains whether the Fagotti score provides an accurate assessment of whether a patient with newly diagnosed, advanced ovarian cancer can achieve a complete resection in surgery.

August 29, 2019

Linda R. Duska, MD, discusses the ongoing debate between upfront surgery and neoadjuvant chemotherapy in ovarian cancer and the data that support both options.

August 28, 2019

Linda R. Duska, MD, discusses neoadjuvant chemotherapy versus upfront surgical debulking in patients with advanced ovarian cancer.

December 26, 2018

Approximately 1 of every 20 Americans will be diagnosed with colorectal cancer at some point in their life, and the American Cancer Society estimates that most colorectal cancer deaths can be prevented by screening.

September 21, 2018

Ryan D. Gentzler, MD, assistant professor, Division of Hematology/Oncology, University of Virginia Health System, discusses combination therapies in non–small cell lung cancer (NSCLC).

August 28, 2018

Dustin M. Walters, MD, provides perspective on the treatment landscape of stage III non–small cell lung cancer.

August 24, 2018

Ryan D. Gentzler, MD, highlights how chemotherapy remains a critical component of the metastatic non–small cell lung cancer treatment paradigm.

August 22, 2018

Richard D. Hall, MD, assistant professor, Hematology/Oncology, University of Virginia Health System, discusses combination approaches in advanced non–small cell lung cancer (NSCLC).

August 21, 2018

Ryan D. Gentzler, MD, assistant professor, Division of Hematology/Oncology, University of Virginia Health System, discusses the role of chemotherapy in patients with metastatic non–small cell lung cancer (NSCLC).

August 15, 2018

James Larner, MD, discusses the process by which radiation interacts with the immune system and how physicians are working to improve treatment responses for patients with non–small cell lung cancer.